Patents by Inventor Ying Ding

Ying Ding has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11911529
    Abstract: A system may automatically conduct hygiene cycles for a confined space such an interior space of a box suitable for storing and/or carrying packaged food. The system may include a hygiene device that can be attached to the box to conduct the hygiene cycles. The system may also automatically collect information related to the hygiene cycles and transmit the collected information to a network.
    Type: Grant
    Filed: March 25, 2022
    Date of Patent: February 27, 2024
    Assignee: Ecolab USA Inc.
    Inventors: Wenbin Wei, Ying Zhang, Zhili Ding, Huarong Yu
  • Publication number: 20230304901
    Abstract: A monitoring device for mangrove soil restoration includes a body, each of four corners of a lower surface of the body is provided with a locking universal wheel, a central position of the body is provided with a piling hole passing through the body, an upper surface of the body is connected to a frame, two inner surfaces of the frame are provided with sliding grooves, the sliding grooves are movably connected to a pile device, a lower surface of the pile device is provided with a round tube, the round tube is disposed above the pilling hole, two sides of the frame are provided with two fixing holes respectively, the two fixing holes are provided a stop rod therethrough. The monitoring device avoids that soil sampling is generally conducted after deep excavation with shovel manually, which saves manpower and the surrounding soil will not affect sampling results.
    Type: Application
    Filed: February 9, 2023
    Publication date: September 28, 2023
    Inventors: Xiaohong Peng, Ying Ding, Shiyi Xie, Shufu Lin, Zhaohong Zhu, Jiahui Chen
  • Publication number: 20230074793
    Abstract: Provided herein, in certain aspects, are methods of treating a cancer in a subject, comprising administering a bispecific anti-CTLA4×anti-PD1 antibody to the subject.
    Type: Application
    Filed: August 5, 2022
    Publication date: March 9, 2023
    Applicant: XENCOR, INC.
    Inventors: Barbara HICKINGBOTTOM, Paul FOSTER, Raphael CLYNES, Ying DING, Lei BAO, Catherine AVERSA-FLEENER
  • Patent number: 10988812
    Abstract: The present invention relates to methods and compositions for determining whether a subject having prostate cancer is at greater risk of developing progressive disease, and methods of treating the subjects. It is based, at least in part, on the discovery that approximately 90% of men carrying at least one of the following fusion genes: TRMT11-GRIK2, SLC45A2-AMACR, MTOR-TP53BP1, LRRC59-FLJ60017, TMEM135-CCDC67 and CCNH-C5orf30 experienced prostate cancer recurrence, metastases and/or prostate cancer-specific death after radical prostatectomy (each examples of “progressive prostate cancer”), while these outcomes occurred in only 36% of men not carrying any of these fusion genes. It is also based, at least in part, on the discovery that no patient studied survived five years without recurrence if their primary prostate cancer contained a TRMT11-GRIK2 or MTOR-TP53BP1 fusion gene. It is also based, at least in part, on the discovery that the protein encoded by the MAN2A1-FER fusion gene exhibits kinase activity.
    Type: Grant
    Filed: May 29, 2019
    Date of Patent: April 27, 2021
    Assignee: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Jianhua Luo, Yangping Yu, Joel B. Nelson, George Konstantine Michalopoulos, Chien-Cheng Tseng, Ying Ding
  • Patent number: 10570460
    Abstract: The present invention relates to methods and compositions for determining whether a subject having prostate cancer is at greater risk of developing progressive disease, and methods of treating the subjects. It is based, at least in part, on the discovery that approximately 90% of men carrying at least one of the following fusion genes: TRMT11-GRIK2, SLC45A2-AMACR, MTOR-TP53BP1, LRRC59-FLJ60017, TMEM135-CCDC67 and CCNH-05orf30 experienced prostate cancer recurrence, metastases and/or prostate cancer-specific death after radical prostatectomy (each examples of “progressive prostate cancer”), while these outcomes occurred in only 36% of men not carrying any of these fusion genes. It is also based, at least in part, on the discovery that no patient studied survived five years without recurrence if their primary prostate cancer contained a TRMT11-GRIK2 or MTOR-TP53BP1 fusion gene. It is also based, at least in part, on the discovery that the protein encoded by the MAN2A1-FER fusion gene exhibits kinase activity.
    Type: Grant
    Filed: November 9, 2018
    Date of Patent: February 25, 2020
    Assignee: UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Jianhua Luo, Yangping Yu, Joel B. Nelson, George Konstantine Michalopoulos, Chien-Cheng Tseng, Ying Ding
  • Publication number: 20190360056
    Abstract: The present invention relates to methods and compositions for determining whether a subject having prostate cancer is at greater risk of developing progressive disease, and methods of treating the subjects. It is based, at least in part, on the discovery that approximately 90% of men carrying at least one of the following fusion genes: TRMT11-GRIK2, SLC45A2-AMACR, MTOR-TP53BP1, LRRC59-FLJ60017, TMEM135-CCDC67 and CCNH-C5orf30 experienced prostate cancer recurrence, metastases and/or prostate cancer-specific death after radical prostatectomy (each examples of “progressive prostate cancer”), while these outcomes occurred in only 36% of men not carrying any of these fusion genes. It is also based, at least in part, on the discovery that no patient studied survived five years without recurrence if their primary prostate cancer contained a TRMT11-GRIK2 or MTOR-TP53BP1 fusion gene. It is also based, at least in part, on the discovery that the protein encoded by the MAN2A1-FER fusion gene exhibits kinase activity.
    Type: Application
    Filed: May 29, 2019
    Publication date: November 28, 2019
    Applicant: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Jianhua Luo, Yangping Yu, Joel B. Nelson, George Konstantine Michalopoulos, Chien-Cheng Tseng, Ying Ding
  • Patent number: 10344338
    Abstract: The present invention relates to methods and compositions for determining whether a subject having prostate cancer is at greater risk of developing progressive disease, and methods of treating the subjects. It is based, at least in part, on the discovery that approximately 90% of men carrying at least one of the following fusion genes: TRMT11-GRIK2, SLC45A2-AMACR, MTOR-TP53BP1, LRRC59-FLJ60017, TMEM135-CCDC67 and CCNH-C5orf30 experienced prostate cancer recurrence, metastases and/or prostate cancer-specific death after radical prostatectomy (each examples of “progressive prostate cancer”), while these outcomes occurred in only 36% of men not carrying any of these fusion genes. It is also based, at least in part, on the discovery that no patient studied survived five years without recurrence if their primary prostate cancer contained a TRMT11-GRIK2 or MTOR-TP53BP1 fusion gene. It is also based, at least in part, on the discovery that the protein encoded by the MAN2A1-FER fusion gene exhibits kinase activity.
    Type: Grant
    Filed: February 14, 2018
    Date of Patent: July 9, 2019
    Assignee: UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Jianhua Luo, Yangping Yu, Joel B. Nelson, George Konstantine Michalopoulos, Chien-Cheng Tseng, Ying Ding
  • Publication number: 20190130290
    Abstract: The present invention involves a method, a system, and software for semantic analysis of disparate data in an environment having a plurality of datasets having distinct information fields. A candidate generation module involves creating graphs with information fields from the plurality of datasets as nodes, then creating smaller graphs containing source and sink vertices based on heuristic values. An electrical network computation module involves representing graphs as an electrical circuit to calculate the voltage of each node and the current of each edge by solving a system of linear equations. A diverse subgraph generation module involves selecting paths that carry the larger amount of current and have more new nodes in an iterative process. With each iteration, the path that scores the highest marginal current per number of existing types of nodes is selected and added to the diverse subgraph.
    Type: Application
    Filed: February 24, 2017
    Publication date: May 2, 2019
    Inventors: Randy Gerard KERBER, Ying DING, Brian FOOTE, David John WILD
  • Patent number: 10239098
    Abstract: Disclosed is an air shower room. The shower room comprises a chamber, an air supply apparatus, an air exhaust apparatus, a sensing mechanism and a controller. The sensing mechanism is disposed at a height inside the chamber and operable to detect presence of the user's arm at the height. The height is chosen such that the user has to raise his arm such that the presence of the arm at the height can be detected by the sensing mechanism. The controller is configured to control operations of the air supply apparatus and the air exhaust apparatus based on the detection by the sensing mechanism. Also disclosed is a dust-free workshop.
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: March 26, 2019
    Assignees: BOE TECHNOLOGY GROUP CO., LTD., BEIJING BOE OPTOELECTRONICS TECHNOLOGY CO., LTD.
    Inventor: Ying Ding
  • Publication number: 20190071733
    Abstract: The present invention relates to methods and compositions for determining whether a subject having prostate cancer is at greater risk of developing progressive disease, and methods of treating the subjects. It is based, at least in part, on the discovery that approximately 90% of men carrying at least one of the following fusion genes: TRMT11-GRIK2, SLC45A2-AMACR, MTOR-TP53BP1, LRRC59-FLJ60017, TMEM135-CCDC67 and CCNH-05orf30 experienced prostate cancer recurrence, metastases and/or prostate cancer-specific death after radical prostatectomy (each examples of “progressive prostate cancer”), while these outcomes occurred in only 36% of men not carrying any of these fusion genes. It is also based, at least in part, on the discovery that no patient studied survived five years without recurrence if their primary prostate cancer contained a TRMT11-GRIK2 or MTOR-TP53BP1 fusion gene. It is also based, at least in part, on the discovery that the protein encoded by the MAN2A1-FER fusion gene exhibits kinase activity.
    Type: Application
    Filed: November 9, 2018
    Publication date: March 7, 2019
    Applicant: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Jianhua Luo, Yangping Yu, Joel B. Nelson, George Konstantine Michalopoulos, Chien-Cheng Tseng, Ying Ding
  • Patent number: 10167519
    Abstract: The present invention relates to methods and compositions for determining whether a subject having prostate cancer is at greater risk of developing progressive disease, and methods of treating the subjects. It is based, at least in part, on the discovery that approximately 90% of men carrying at least one of the following fusion genes: TRMT11-GRIK2, SLC45A2-AMACR, MTOR-TP53BP1, LRRC59-FLJ60017, TMEM135-CCDC67 and CCNH-05orf30 experienced prostate cancer recurrence, metastases and/or prostate cancer-specific death after radical prostatectomy (each examples of “progressive prostate cancer”), while these outcomes occurred in only 36% of men not carrying any of these fusion genes. It is also based, at least in part, on the discovery that no patient studied survived five years without recurrence if their primary prostate cancer contained a TRMT11-GRIK2 or MTOR-TP53BP1 fusion gene. It is also based, at least in part, on the discovery that the protein encoded by the MAN2A1-FER fusion gene exhibits kinase activity.
    Type: Grant
    Filed: February 14, 2018
    Date of Patent: January 1, 2019
    Assignee: UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Jianhua Luo, Yangping Yu, Joel B. Nelson, George Konstantine Michalopoulos, Chien-Cheng Tseng, Ying Ding
  • Patent number: 10163762
    Abstract: A semiconductor assembly includes a semiconductor die comprising lower and upper electrical contacts. A lead frame having a lower die pad is electrically and mechanically connected to the lower electrical contact of the die. An upper conductive member has a first portion electrically and mechanically connected to the upper electrical contact of the die. A lead terminal has a surface portion electrically and mechanically connected to a second portion of the conductive member. The surface portion of the lead terminal and/or the second portion of the conductive member has a series of grooves disposed therein. Packaging material encapsulates the semiconductor die, at least a portion of the lead frame, at least a portion of the upper conducive member and at least a portion of the lead terminal.
    Type: Grant
    Filed: June 10, 2015
    Date of Patent: December 25, 2018
    Assignee: VISHAY GENERAL SEMICONDUCTOR LLC
    Inventors: Hui-Ying Ding, Pengnian Wang, Tao Yu, Jun-Feng Liu, Jun-Kai Bai, Chih-Ping Peng
  • Publication number: 20180245162
    Abstract: The present invention relates to methods and compositions for determining whether a subject having prostate cancer is at greater risk of developing progressive disease, and methods of treating the subjects. It is based, at least in part, on the discovery that approximately 90% of men carrying at least one of the following fusion genes: TRMT11-GRIK2, SLC45A2-AMACR, MTOR-TP53BP1, LRRC59-FLJ60017, TMEM135-CCDC67 and CCNH-C5orf30 experienced prostate cancer recurrence, metastases and/or prostate cancer-specific death after radical prostatectomy (each examples of “progressive prostate cancer”), while these outcomes occurred in only 36% of men not carrying any of these fusion genes. It is also based, at least in part, on the discovery that no patient studied survived five years without recurrence if their primary prostate cancer contained a TRMT11-GRIK2 or MTOR-TP53BP1 fusion gene. It is also based, at least in part, on the discovery that the protein encoded by the MAN2A1-FER fusion gene exhibits kinase activity.
    Type: Application
    Filed: February 14, 2018
    Publication date: August 30, 2018
    Applicant: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Jianhua Luo, Yangping Yu, Joel B. Nelson, George Konstantine Michalopoulos, Chien-Cheng Tseng, Ying Ding
  • Publication number: 20180187268
    Abstract: The present invention relates to methods and compositions for determining whether a subject having prostate cancer is at greater risk of developing progressive disease, and methods of treating the subjects. It is based, at least in part, on the discovery that approximately 90% of men carrying at least one of the following fusion genes: TRMT11-GRIK2, SLC45A2-AMACR, MTOR-TP53BP1, LRRC59-FLJ60017, TMEM135-CCDC67 and CCNH-05orf30 experienced prostate cancer recurrence, metastases and/or prostate cancer-specific death after radical prostatectomy (each examples of “progressive prostate cancer”), while these outcomes occurred in only 36% of men not carrying any of these fusion genes. It is also based, at least in part, on the discovery that no patient studied survived five years without recurrence if their primary prostate cancer contained a TRMT11-GRIK2 or MTOR-TP53BP1 fusion gene. It is also based, at least in part, on the discovery that the protein encoded by the MAN2A1-FER fusion gene exhibits kinase activity.
    Type: Application
    Filed: February 14, 2018
    Publication date: July 5, 2018
    Applicant: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Jianhua Luo, Yangping Yu, Joel B. Nelson, George Konstantine Michalopoulos, Chien-Cheng Tseng, Ying Ding
  • Patent number: 9932641
    Abstract: The present invention relates to methods and compositions for determining whether a subject having prostate cancer is at greater risk of developing progressive disease, and methods of treating the subjects. It is based, at least in part, on the discovery that approximately 90% of men carrying at least one of the following fusion genes: TRMT11-GRIK2, SLC45A2-AMACR, MTOR-TP53BP1, LRRC59-FLJ60017, TMEM135-CCDC67 and CCNH-C5orf30 experienced prostate cancer recurrence, metastases and/or prostate cancer-specific death after radical prostatectomy (each examples of “progressive prostate cancer”), while these outcomes occurred in only 36% of men not carrying any of these fusion genes. It is also based, at least in part, on the discovery that no patient studied survived five years without recurrence if their primary prostate cancer contained a TRMT11-GRIK2 or MTOR-TP53BP1 fusion gene. It is also based, at least in part, on the discovery that the protein encoded by the MAN2A1-FER fusion gene exhibits kinase activity.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: April 3, 2018
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Jianhua Luo, Yangping Yu, Joel B. Nelson, George Konstantine Michalopoulos, Chien-Cheng Tseng, Ying Ding
  • Publication number: 20170080465
    Abstract: Disclosed is an air shower room. The shower room comprises a chamber, an air supply apparatus, an air exhaust apparatus, a sensing mechanism and a controller. The sensing mechanism is disposed at a height inside the chamber and operable to detect presence of the user's arm at the height. The height is chosen such that the user has to raise his arm such that the presence of the arm at the height can be detected by the sensing mechanism. The controller is configured to control operations of the air supply apparatus and the air exhaust apparatus based on the detection by the sensing mechanism. Also disclosed is a dust-free workshop.
    Type: Application
    Filed: April 28, 2016
    Publication date: March 23, 2017
    Inventor: Ying Ding
  • Publication number: 20160376666
    Abstract: The present invention relates to methods and compositions for determining whether a subject having prostate cancer is at greater risk of developing progressive disease, and methods of treating the subjects. It is based, at least in part, on the discovery that approximately 90% of men carrying at least one of the following fusion genes: TRMT11-GRIK2, SLC45A2-AMACR, MTOR-TP53BP1, LRRC59-FLJ60017, TMEM135-CCDC67 and CCNH-C5orf30 experienced prostate cancer recurrence, metastases and/or prostate cancer-specific death after radical prostatectomy (each examples of “progressive prostate cancer”), while these outcomes occurred in only 36% of men not carrying any of these fusion genes. It is also based, at least in part, on the discovery that no patient studied survived five years without recurrence if their primary prostate cancer contained a TRMT11-GRIK2 or MTOR-TP53BP1 fusion gene. It is also based, at least in part, on the discovery that the protein encoded by the MAN2A1-FER fusion gene exhibits kinase activity.
    Type: Application
    Filed: June 30, 2016
    Publication date: December 29, 2016
    Applicant: University Of Pittsburgh - Of The Commonwealth System Of Higher Education
    Inventors: JIANHUA LUO, Yangping Yu, Joel B. Nelson, George Konstantine Michalopoulos, Chien-Cheng Tseng, Ying Ding
  • Publication number: 20160365305
    Abstract: A semiconductor assembly includes a semiconductor die comprising lower and upper electrical contacts. A lead frame having a lower die pad is electrically and mechanically connected to the lower electrical contact of the die. An upper conductive member has a first portion electrically and mechanically connected to the upper electrical contact of the die. A lead terminal has a surface portion electrically and mechanically connected to a second portion of the conductive member. The surface portion of the lead terminal and/or the second portion of the conductive member has a series of grooves disposed therein. Packaging material encapsulates the semiconductor die, at least a portion of the lead frame, at least a portion of the upper conducive member and at least a portion of the lead terminal.
    Type: Application
    Filed: June 10, 2015
    Publication date: December 15, 2016
    Inventors: Hui-Ying Ding, Pengnian Wang, Tao Yu, Jun-Feng Liu, Jun-Kai Bai, Chih-Ping Peng
  • Patent number: 9041188
    Abstract: An axially-mountable device includes a semiconductor chip comprising lower and upper electrical contacts. A lower die pad is electrically and mechanically connected to the lower electrical contact of the chip. An upper die pad is electrically and mechanically connected to the upper electrical contact of the chip. A first axially extending electrical lead is electrically and mechanically connected to the upper die pad and extends in a first axial direction. A second axially extending electrical lead is electrically and mechanically connected to the lower die pad and extends in a second axial direction that is opposite to the first axial direction. Packaging material encapsulates the semiconductor chip, the upper and lower die pads and a portion of the first and second axially extending leads. The first and second leads extend from the packaging material and are adapted to allow the device to be axially-mounted with another electrical component.
    Type: Grant
    Filed: November 10, 2012
    Date of Patent: May 26, 2015
    Assignee: VISHAY GENERAL SEMICONDUCTOR LLC
    Inventors: Wan-Lan Chiang, Chih-Ping Peng, Hui-Ying Ding
  • Publication number: 20140320537
    Abstract: The present disclosure relates to a method, a device and a storage medium for controlling an electronic map. The method includes: detecting a first user operation, configured for setting a viewing angle of the electronic map; in response to the first user operation, setting the viewing angle of the electronic map; and if no first user operation being detected within a predetermined length of time, setting the viewing angle of the electronic map according a posture of the electronic apparatus detected at current time.
    Type: Application
    Filed: July 3, 2014
    Publication date: October 30, 2014
    Inventors: YING-FENG ZHANG, MU WANG, YING-DING HE